- Home
- SHMD vs IMAB Comparison
SHMD vs IMAB Comparison
Compare SHMD & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- IMAB
- Stock Information
- Founded
- SHMD 1864
- IMAB 2014
- Country
- SHMD Germany
- IMAB United States
- Employees
- SHMD N/A
- IMAB N/A
- Industry
- SHMD
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- IMAB Health Care
- Exchange
- SHMD Nasdaq
- IMAB Nasdaq
- Market Cap
- SHMD 123.6M
- IMAB 200.9M
- IPO Year
- SHMD N/A
- IMAB 2020
- Fundamental
- Price
- SHMD $2.77
- IMAB $2.45
- Analyst Decision
- SHMD
- IMAB Strong Buy
- Analyst Count
- SHMD 0
- IMAB 2
- Target Price
- SHMD N/A
- IMAB $6.00
- AVG Volume (30 Days)
- SHMD 24.1K
- IMAB 1.2M
- Earning Date
- SHMD 02-25-2025
- IMAB 05-15-2025
- Dividend Yield
- SHMD N/A
- IMAB N/A
- EPS Growth
- SHMD N/A
- IMAB N/A
- EPS
- SHMD N/A
- IMAB N/A
- Revenue
- SHMD $85,165,542.00
- IMAB N/A
- Revenue This Year
- SHMD N/A
- IMAB N/A
- Revenue Next Year
- SHMD N/A
- IMAB N/A
- P/E Ratio
- SHMD N/A
- IMAB N/A
- Revenue Growth
- SHMD N/A
- IMAB N/A
- 52 Week Low
- SHMD $1.86
- IMAB $0.60
- 52 Week High
- SHMD $5.17
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- IMAB 50.05
- Support Level
- SHMD N/A
- IMAB $2.35
- Resistance Level
- SHMD N/A
- IMAB $2.59
- Average True Range (ATR)
- SHMD 0.00
- IMAB 0.35
- MACD
- SHMD 0.00
- IMAB -0.06
- Stochastic Oscillator
- SHMD 0.00
- IMAB 1.86
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).